Abstract:Abstract 5048 Background and Objectives: Myelodysplastic syndrome (MDS) is one of the most threatening hematological malignancies. Recently, the epigenetic changes have been recognized in the MDS, and some research found that the aberrant DNA methylation had close relationship with the MDS. Meanwhile, some studies showed that the activation of the Wnt signaling pathway and abnormal methylation of the Wnt antagonists had close relationship with hematological malignancies, such as AML AALL Aand CLL, but less is known in MDS. In our research, we studied the methylation status of Wnt antagonists (DKK1, DKK3, HDPR1, WIF-1, SFRP1 and SFRP4) in the patients with MDS and evaluated the role of them in the pathogenesis and progression of MDS, with providing a new theory support for clarifying the complicated pathogenesis and progression of MDS. Methods: The methylation status of Wnt antagonists (DKK1, DKK3, HDPR1, WIF-1, SFRP1 and SFRP4) in pretreatment bone marrow samples from 53 patients with MDS was measured by methylation-specific polymerase chain reaction (MSP). On the other hand, we collected the clinical materials of the patients with MDS and follow up the patients. Then the correlation between methylation and clinical features as well as prognosis of MDS patients was analyzed byχ2 test and Kaplan-Meier method. Results: In 53 bone marrow samples, the methylation frequencies of the Wnt antagonists were as follows: SFRP4 for 62.3 % (33/53), DKK1 for 45.3 % (24/53), HDPR1 for 34.0 % (18/53), SFRP1 for 15.1 % (8/53), DKK3 for 9.4 % (5/53), and WIF-1 for 5.7 % (3/53). After analyzing individual tumor suppressor gene, clinical parameters and prognostic information, it was found that the patients with the percentage of BM blast above 5% had higher methylation frequency of HDPR1 than the patients with the percentage of BM blast bellow 5% (44.4%∼a13.3%, P=0.034); besides, the methylation frequency of HDPR1 exhibited significant differences in the MDS subtypes (P=0.019), and was significantly correlated with the WPSS (P=0.037); In addition, Kaplan-Meier survival curve indicated that the mean overall survival of patients with methylation was significantly shorter than that of patients without HDPR1 methylation (457.3 days vs. 919.6 days, P=0.037) (Fig.1). Conclusion: The methylation of the Wnt antagonists (DKK1, DKK3, HDPR1, WIF-1, SFRP1 and SFRP4) were observed in patients with MDS and their methylation frequencies were different. The aberrant methylation of HDPR1 may play an important role in the progression and prognosis of MDS. Disclosures: No relevant conflicts of interest to declare.

Identification of Aberrant Methylation of DLC-1 by Pyrosequencing in Acute Lymphoblastic Leukemia in Children

The Methylation Pattern of LRP15 Gene in Acute Leukemia

Methylation Analysis of the Wnt Antagonist in Myelodysplastic Syndrome

Tumor-Specific Methylation of the 8p22 Tumor Suppressor Gene DLC1 is an Epigenetic Biomarker for Hodgkin, Nasal NK/T-Cell and Other Types of Lymphomas

Identification of DLC-1 Expression and Methylation Status in Patients with Non-Small-cell Lung Cancer

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

Detection and Clinical Significance of DLC1 Gene Methylation in Serum DNA from Colorectal Cancer Patients

Promoter Methylation and Expression of DLC-1 Gene in Human Colon Cell Lines

Aberrant methylation of DLC-1 promoter in retinoblastoma

Aberrant Methylation and Deacetylation of Deleted in Liver Cancer-1 Gene in Prostate Cancer: Potential Clinical Applications.

Genetic Alterations of DLC1 in Medulloblastoma and Primitive Neuroectodermal Tumor

Abberant Promoter Hypermethylation of AKAP12 Gene in Acute Lymphoblastic Leukemia in Children

A Novel Method of Microarray Quantitave Analysis of P16 CPG Island Methylation in Leukemia Cells from Patients with Hematological Malignancies.

Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma.

Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact

The clinical values of dysregulated DNA methylation and demethylation intermediates in acute lymphoblastic leukemia.

Protein expression and promoter methylation of the deleted in liver cancer-1 gene in papillary thyroid carcinoma

The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma

Methylation of DAPK1 Gene Promoter's CpG Island and Its Role in the Pathogenic Mechanism of Leukemia

Epigenetic Silencing of the 3p22 Tumor Suppressor DLEC1 by Promoter CpG Methylation in Non-Hodgkin and Hodgkin Lymphomas

Promoter Hypermethylation along with LOH, but Not Mutation, Contributes to Inactivation of DLC-1 in Nasopharyngeal Carcinoma.